Subject(s)
Aortic Valve Insufficiency , Aortic Valve Stenosis , Pulmonary Valve , Child , Humans , Adolescent , Aortic Valve Insufficiency/surgery , Autografts , Dilatation , Aortic Valve/transplantation , Aortic Valve Stenosis/surgery , Transplantation, Autologous , Pulmonary Valve/transplantation , Follow-Up Studies , Treatment Outcome , Retrospective StudiesABSTRACT
Infectious endocarditis is a severe infectious disease in cardiovascular surgery fields. Appropriate antibiotics administration is the principle of treatment, while surgical intervention is required when there is intensive tissue destruction, refractory infection, or high risk of embolism. Usually, surgical risks of infectious endocarditis are rather high as preoperative general condition is often poor. Homografts, which have excellent anti-infective properties, become one of the graft options for infectious endocarditis. Fortunately, we are able to use homografs without so much obstacles thanks to the presence of a tissue bank in our hospital. We will report our strategy and clinical courses of aortic root replacement using homograft for infective endocarditis.
Subject(s)
Endocarditis, Bacterial , Endocarditis , Heart Valve Prosthesis , Humans , Aortic Valve/transplantation , Endocarditis, Bacterial/surgery , Transplantation, Homologous , Endocarditis/surgery , AllograftsSubject(s)
Aortic Valve Insufficiency , Heart Valve Diseases , Pulmonary Valve , Humans , Transplantation, Autologous , Autografts , Biomechanical Phenomena , Heart Valve Diseases/surgery , Aortic Valve/transplantation , Pulmonary Valve/transplantation , Aortic Valve Insufficiency/surgery , Follow-Up Studies , Reoperation , Treatment OutcomeSubject(s)
Aortic Valve Insufficiency , Heart Valve Prosthesis , Humans , Aortic Valve/surgery , Aortic Valve/transplantation , Aortic Valve Insufficiency/diagnostic imaging , Aortic Valve Insufficiency/etiology , Aortic Valve Insufficiency/surgery , Transplantation, Homologous , Allografts , CryopreservationABSTRACT
Aortic root pseudoaneurysm is often derived from suture sites after aortic root replacement on the basis of connective tissue disease, aortitis, or prosthetic valve endocarditis. Preoperative computed tomography (CT) and echocardiography are useful not only for diagnosing a pseudoaneurysm but also for planning to repair it. Redo aortic root replacement is necessary to repair it in most cases. When a giant pseudoaneurysm is close to a sternal posterior wall, resternotomy may be challenging. In such a case, precedent cardiopulmonary bypass with left ventricular apical vent under mild-moderate hypothermia is useful to control bleeding during resternotomy. Regarding graft selection, cryopreserved homograft is effective for repairing pseudoaneurysm in an active infectious phase, but modified Bentall procedure may be still considerable to expect long-term durability if infection is well controlled by preoperative sufficient antibiotic treatment and intraoperative debridement. In the author's institute, 45 patients with aortic root pseudoaneurysm underwent surgical repair since 2011. Thirty cases (67%) was infectious. Thirty-six patients( 80%) underwent aortic root replacement, including homograft in 14 patients and modified Bentall procedure in 22 patients. All the patients survived at discharge, and 1-year and 5-year survival were 96.8% and 74.9%, respectively. Preoperative infectious status and graft selection did not significantly affect remote-phase survival.
Subject(s)
Aneurysm, False , Endocarditis, Bacterial , Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Aneurysm, False/diagnostic imaging , Aneurysm, False/surgery , Anti-Bacterial Agents , Aortic Valve/transplantation , Endocarditis, Bacterial/surgery , HumansABSTRACT
OBJECTIVES: The aim of this retrospective study was to assess the early- and long-term outcomes following the use of cryopreserved allografts in aortic valve endocarditis with peri-annular abscess formation. METHODS: From 2001 to 2021, 110 consecutive patients with active infective endocarditis and peri-annular abscess, underwent a cryopreserved allograft root replacement. In 100 patients (91%), the operation was performed <48 h after admission due to refractory heart failure and or septic shock. In 95 patients (86.4%), a redo operation was performed due to a prosthetic valve endocarditis. Preoperatively, 12 patients were dialysis-dependent and 30 patients suffered from a recent stroke. RESULTS: The 30-day mortality was 18% (20 patients). Freedom from reintervention was 98.3% (standard deviation: 1.7) at 1 year and 83.3% (standard deviation: 8.5) at 10 years. Four patients required a redo operation. Three patients did develop re-endocarditis. Freedom from re-endocarditis was 95% after 17 years of follow-up. Preoperative dialysis dependency (odds ratio: 22.75, 95% confidence interval: 4.79-108.14, P < 0.001), ejection fraction under 30% (odds ratio: 17.91, 95% confidence interval: 3.27-98.01, P < 0.001) and stroke within 14 days prior to operation (odds ratio: 5.21, 95% confidence interval: 1.28-21.2, P = 0.021) were incremental factors associated with the 30-day mortality. CONCLUSIONS: In aortic root endocarditis with abscesses formation, cryopreserved allografts exhibit excellent clinical performance with a low rate of reinfection and reintervention, which make its use as valve replacement a very desirable option. Dialysis dependency, ejection fraction under 30% and recent stroke have the highest impact on the 30-day mortality.
Subject(s)
Endocarditis, Bacterial , Endocarditis , Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Stroke , Abscess/etiology , Abscess/surgery , Allografts/surgery , Aortic Valve/surgery , Aortic Valve/transplantation , Endocarditis/surgery , Endocarditis, Bacterial/surgery , Heart Valve Prosthesis Implantation/adverse effects , Humans , Reoperation , Retrospective StudiesSubject(s)
Endocarditis , Heart Valve Prosthesis , Allografts , Aorta/surgery , Aortic Valve/transplantation , Endocarditis/surgery , HumansABSTRACT
OBJECTIVES: The aim of this study was to evaluate early- and long-term outcomes of cryopreserved aortic homograft (CAH) implantation for aortic valve replacement (AVR) or aortic root replacement (ARR) in patients with or without complex infective endocarditis. METHODS: All adult patients undergoing AVR or ARR with CAH at our institution between January 1993 and July 2021 were included in the study. RESULTS: One hundred four patients, 75 males and 29 females, aged 59 ± 17 years, underwent AVR or ARR with CAH for infective endocarditis (n = 94, 90%) or aortic valve disease (n = 10, 10%). There were 33 (35%) native valve endocarditis and 61 (65%) prosthetic valve endocarditis, which were complicated by annular abscess in 77 (82%) patients, mitral valve endocarditis in 13 (14%) and tricuspid valve endocarditis in 13 (14%). The mean cardiopulmonary bypass time was 214 ± 80 min and the mean aortic cross-clamping time was 164 ± 56 min. There were 12 (12%) hospital deaths and 7 (7%) postoperative low cardiac output syndrome requiring extracorporeal membrane oxygenation in 4 patients and intra-aortic balloon pump in 3. Thirty-nine (42%) patients died during the follow-up (94% complete). The mean survival time was 13.9 ± 1.2 years. Twenty-five patients (26%) underwent late reoperation for aortic homograft degeneration (n = 17, 18%), homograft endocarditis (n = 6, 7%), homograft dehiscence (n = 1, 1%) and mitral valve regurgitation (n = 1, 1%). The mean survival free from reintervention was 15.7 ± 1.2 years. CONCLUSIONS: AVR or ARR with a CAH for complex endocarditis is associated with satisfactory hospital survival, considering the critical patient presentation at surgery, and excellent survival free from recurrent infection. Need for reoperation late after surgery is similar to other biological prostheses.
Subject(s)
Endocarditis, Bacterial , Endocarditis , Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Adult , Allografts/surgery , Aortic Valve/transplantation , Endocarditis/surgery , Endocarditis, Bacterial/surgery , Female , Follow-Up Studies , Heart Valve Prosthesis/adverse effects , Heart Valve Prosthesis Implantation/adverse effects , Humans , Male , ReoperationABSTRACT
ABSTRACT: Aortic valve replacement for severe stenosis is a standard procedure in cardiovascular medicine. However, the use of biological prostheses has limitations especially in young patients because of calcifying degeneration, resulting in implant failure. Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, was shown to decrease the degeneration of native aortic valves. In this study, we aim to examine the impact of pioglitazone on inflammation and calcification of aortic valve conduits (AoC) in a rat model. Cryopreserved AoC (n = 40) were infrarenally implanted into Wistar rats treated with pioglitazone (75 mg/kg chow; n = 20, PIO) or untreated (n = 20, controls). After 4 or 12 weeks, AoC were explanted and analyzed by histology, immunohistology, and polymerase chain reaction. Pioglitazone significantly decreased the expression of inflammatory markers and reduced the macrophage-mediated inflammation in PIO compared with controls after 4 (P = 0.03) and 12 weeks (P = 0.012). Chondrogenic transformation was significantly decreased in PIO after 12 weeks (P = 0.001). Calcification of the intima and media was significantly reduced after 12 weeks in PIO versus controls (intima: P = 0.008; media: P = 0.025). Moreover, echocardiography revealed significantly better functional outcome of the AoC in PIO after 12 weeks compared with control. Interestingly, significantly increased intima hyperplasia could be observed in PIO compared with controls after 12 weeks (P = 0.017). Systemic PPAR-gamma activation prevents inflammation as well as intima and media calcification in AoC and seems to inhibit functional impairment of the implanted aortic valve. To further elucidate the therapeutic role of PPAR-gamma regulation for graft durability, translational studies and long-term follow-up data should be striven for.
Subject(s)
Aortic Valve Insufficiency/surgery , Aortic Valve/drug effects , Aortic Valve/transplantation , Bioprosthesis , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis , PPAR gamma/agonists , Pioglitazone/pharmacology , Animals , Aortic Valve/metabolism , Aortic Valve/pathology , Aortic Valve Insufficiency/metabolism , Aortic Valve Insufficiency/pathology , Calcinosis/metabolism , Calcinosis/pathology , Calcinosis/prevention & control , Chondrogenesis/drug effects , Cryopreservation , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Heart Valve Prosthesis Implantation/adverse effects , Humans , Inflammation Mediators/metabolism , Osteogenesis/drug effects , PPAR gamma/metabolism , Rats, Sprague-Dawley , Rats, Wistar , Signal TransductionABSTRACT
Transcatheter aortic valve replacement (TAVR) has shown to reduce mortality compared to surgical aortic valve replacement (sAVR). However, it is unknown which procedure is associated with better post-procedural valvular function. We conducted a meta-analysis of randomized clinical trials that compared TAVR to sAVR for at least 2 years. The primary outcome was post-procedural patient-prosthesis-mismatch (PPM). Secondary outcomes were post-procedural and 2-year: effective orifice area (EOA), paravalvular gradient (PVG) and moderate/severe paravalvular leak (PVL). We identified 6 trials with a total of 7022 participants with severe aortic stenosis. TAVR was associated with 37% (95% CI [0.51-0.78) mean RR reduction of post-procedural PPM, a decrease that was not affected by the surgical risk at inclusion, neither by the transcatheter heart valve system. Postprocedural changes in gradient and EOA were also in favor of TAVR as there was a pooled mean difference decrease of 0.56 (95% CI [0.73-0.38]) in gradient and an increase of 0.47 (95% CI [0.38-0.56]) in EOA. Additionally, self-expandable valves were associated with a higher decrease in gradient than balloon ones (beta = 0.38; 95% CI [0.12-0.64]). However, TAVR was associated with a higher risk of moderate/severe PVL (pooled RR: 9.54, 95% CI [5.53-16.46]). All results were sustainable at 2 years.
Subject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/transplantation , Transcatheter Aortic Valve Replacement/methods , Aged , Aged, 80 and over , Female , Follow-Up Studies , Heart Valve Prosthesis , Humans , Male , Risk Assessment , Risk Factors , Severity of Illness Index , Treatment OutcomeABSTRACT
BACKGROUND: Aortic homografts have been used in young patients requiring aortic valve replacement. Currently, these grafts are generally reserved for aortic valve endocarditis with or without root abscess; however, longitudinal data are lacking. Our aim was to assess the long-term safety and durability of homograft implantation. METHODS: All adult patients undergoing aortic homograft implantation at a single institution from 1992 to 2019 were included. Outcomes of interest included all-cause mortality and aortic valve reoperation, studied over a median follow-up duration of 19 years. RESULTS: In all, 252 patients with a mean age of 49 years were included. Infective endocarditis was the primary indication for surgery in 95 patients (38%). The endocarditis group, compared with the no-endocarditis group, had a higher prevalence of New York Heart Association class III-IV (56% vs 26%), chronic kidney disease (22% vs 1%), prior cardiac surgery (40% vs 10%), and emergency status (7% vs 0%; all P < .001). Operative mortality was higher among endocarditis patients (16% vs 0.6%, P < .001), which persisted after risk adjustment. Among patients who survived to discharge, however, there was no difference in long-term survival between the endocarditis group and no-endocarditis group. Overall survival and freedom from reoperation were 88.3% and 80% at 15 years and 87.2% and 78% at 25 years, respectively. Indications for reoperation included structural valve deterioration (83%), endocarditis (12%), and mitral valve disease (5%). Reoperative mortality occurred in 2 patients (4.9%). CONCLUSIONS: Aortic homografts are associated with good long-term survival and admissible freedom from reoperation. Operative mortality is high among patients with endocarditis; however, for those who survive to discharge, long-term survival and durability are the same as for patients without endocarditis.
Subject(s)
Aortic Valve/transplantation , Forecasting , Heart Valve Diseases/surgery , Heart Valve Prosthesis Implantation/methods , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Transplantation, Homologous , Treatment OutcomeSubject(s)
Aortic Valve/surgery , Endocarditis, Bacterial/diagnosis , Heart Ventricles/surgery , Staphylococcal Infections/diagnosis , Aortic Valve/transplantation , Diagnosis, Differential , Endocarditis, Bacterial/diagnostic imaging , Endocarditis, Bacterial/surgery , Female , Heart Valve Prosthesis Implantation , Humans , Middle Aged , Rheumatic Heart Disease/surgery , Staphylococcal Infections/diagnostic imaging , Staphylococcal Infections/surgery , Video RecordingABSTRACT
BACKGROUND: Donor heart shortage has extended the waiting time and increased the mortality of patients on the transplant waiting list. Widening old standard donor criteria has successfully increased the number of heart transplantations, but for many years, a valve disease in a donor heart has been considered a primary contraindication for organ donation. AIMS: To analyse the results of aortic and mitral valvular surgery in marginal donor hearts with valvulopathy before orthotopic heart transplantation. METHODS: Between January 2012 and November 2015, we performed 53 heart transplantations in our department. In four donors, echocardiography performed at the time of organ procurement showed a valvular disease: three had moderate-to-severe mitral regurgitation; and one had moderately severe aortic valve stenosis. RESULTS: The mean bench mitral repair and aortic replacement time, aortic cross-clamp time and total ischaemic time were: 18 (range 7-25) minutes, 78.7 (range 57-98) minutes and 184 (range 89-255) minutes, respectively. Intraoperative transoesophageal echocardiography showed good mitral repair or aortic prosthetic valve function, and good right and left ventricular function. One patient died of infectious pneumonia after 1 month. The mean duration of follow-up for the patients discharged home was 75±13 months, and all have returned to an active unrestricted lifestyle. CONCLUSIONS: Our limited series demonstrates that conventional valvular procedures performed on otherwise healthy donor hearts with mitral and aortic valve pathology can efficaciously expand the donor pool for orthotopic cardiac transplantation and decrease the mortality rate on the waiting list.
Subject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/pathology , Aortic Valve/transplantation , Calcinosis/surgery , Donor Selection , Heart Failure/surgery , Heart Transplantation , Heart Valve Prosthesis Implantation , Mitral Valve Annuloplasty , Mitral Valve Insufficiency/surgery , Mitral Valve/transplantation , Tissue Donors/supply & distribution , Aortic Valve/diagnostic imaging , Aortic Valve/physiopathology , Aortic Valve/surgery , Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/physiopathology , Calcinosis/diagnostic imaging , Calcinosis/physiopathology , Feasibility Studies , Female , Graft Survival , Heart Failure/diagnostic imaging , Heart Failure/physiopathology , Heart Transplantation/adverse effects , Humans , Male , Middle Aged , Mitral Valve/diagnostic imaging , Mitral Valve/physiopathology , Mitral Valve Annuloplasty/adverse effects , Mitral Valve Insufficiency/diagnostic imaging , Mitral Valve Insufficiency/physiopathology , Recovery of Function , Risk Factors , Time Factors , Treatment OutcomeABSTRACT
The implantation of a decellularized aortic homograft in children and young adults has been shown to be a good alternative to existing surgical approaches. Lower risk of calcification and the potential of growth render a homograft a promising valve substitute. The child presented in this video tutorial is a 10-year-old boy diagnosed with congenital aortic stenosis which was treated by balloon valvuloplasty early in life. Current echocardiographic findings show severe aortic regurgitation and stenosis. The tutorial provides detailed insight into how to implant a decellularized aortic homograft as a total root replacement.
Subject(s)
Aortic Valve Insufficiency/surgery , Aortic Valve Stenosis/congenital , Aortic Valve Stenosis/surgery , Aortic Valve/transplantation , Balloon Valvuloplasty , Allografts , Aortic Valve Insufficiency/etiology , Child , Echocardiography , Humans , Male , Transplantation, HomologousABSTRACT
Background and objectives: Plasma arginine vasopressin (P-AVP) is regulated by the non-osmotic pathway in patients with heart failure (HF) and reduced ejection fraction. However, the regulation of P-AVP in patients with severe aortic stenosis (AS) remains unknown. Materials and Methods: Consecutive patients with severe AS who received trans-catheter aortic valve implantation (TAVI) between Apr 2016 and Apr 2019 were enrolled in this prospective study. Clinical data including P-AVP were obtained just before TAVI, and the correlation between P-AVP and other variables was investigated. Results: In total, 159 patients with severe AS (85.3 ± 4.6 years, male 26%) were enrolled. P-AVP was 1.45 ± 1.13 ng/mL and cardiac index was relatively preserved (2.76 ± 0.54 L/min/m2). There was no significant correlation between cardiac index and P-AVP (p > 0.05), whereas plasma osmolality had a moderate positive correlation with P-AVP (r = 0.35, p < 0.01), predominantly due to blood urea nitrogen (r = 0.27, p < 0.01). Patients with diuretics had significantly higher P-AVP than those without diuretics (1.65 ± 1.43 vs. 1.22 ± 0.57 pg/mL, p < 0.01). Two-year survivals free from HF readmission were statistically comparable irrespective of the level of pre-procedural P-AVP (p = 0.44). Conclusion: In patients with severe high-gradient AS who received TAVI, the P-AVP level was dominantly regulated by plasma osmolality instead of arterial underfilling. The clinical implication of elevated P-AVP in the TAVI candidates is the next concern.
Subject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/abnormalities , Arginine Vasopressin/therapeutic use , Heart Valve Prosthesis Implantation/standards , Aged , Aged, 80 and over , Aortic Valve/surgery , Aortic Valve/transplantation , Aortic Valve Stenosis/drug therapy , Arginine Vasopressin/pharmacology , Female , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis Implantation/trends , Humans , Male , Prospective Studies , Statistics, NonparametricABSTRACT
PURPOSE: Accurately reproducing physiological and time-varying variables in cardiac bioreactors is a difficult task for conventional control methods. This paper presents a new controller based on a genetic algorithm for the control of a cardiac bioreactor dedicated to the study and conditioning of heart valve substitutes. METHODS: A multi-objective genetic algorithm was designed to obtain an accurate simultaneous reproduction of physiological periodic time functions of the three most relevant variables characterizing the blood flow in the aortic valve. These three controlled variables are the flow rate and the pressures upstream and downstream of the aortic valve. RESULTS: Experimental results obtained with this new algorithm showed an accurate dynamic reproduction of these three controlled variables. Moreover, the controller can react and adapt continuously to changes happening over time in the cardiac bioreactor, which is a major advantage when working with living biological valve substitutes. CONCLUSION: The strong non-linear interaction that exists between the three controlled variables makes it difficult to obtain a precise control of any of these, let alone all three simultaneously. However, the results showed that this new control algorithm can efficiently overcome such difficulties. In the particular field of bioreactors reproducing the cardiovascular environment, such a flexible, versatile and accurate reproduction of these three interdependent controlled variables is unprecedented.
Subject(s)
Algorithms , Aortic Valve/physiology , Bioprosthesis , Bioreactors , Blood Pressure , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis , Tissue Engineering/instrumentation , Aortic Valve/transplantation , Blood Flow Velocity , Cells, Cultured , Humans , Mechanotransduction, Cellular , Stress, Mechanical , Time Factors , Tissue Culture TechniquesABSTRACT
The angle correction feature in ultrasound systems is used when there is difficulty accurately aligning the Doppler beam with the flow to be interrogated. The operator can manually "correct" the angle to the actual direction of flow. Subsequently, the machine corrects the peak velocity for the angle. We present a case of aortic valve replacement (AVR) in which falsely high transaortic gradients were obtained immediately after separation from cardiopulmonary bypass (CPB). We recommend that there be a more prominent notification when the angle correction feature is used with machine prompts confirming when a peak velocity is obtained using angle correction.